| 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation.
Grab Sources And More Here: CTOR Presentation. -----
And as I mentioned previously, (Nasdaq: CTOR) has several potential catalysts helping catapult it to the top of our watchlist. Take a look:
#1. CTOR Potential Catalyst - Could A Very Low Float Create An Environment For Heightened Volatility Potential?
According to the Yahoo Finance website, CTOR has a very low float.
In fact, the website reports this profile to have approximately 3.44Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could even more positive company news at the end of 2025 provide a breakout spark when paired with this volatility potential? -----
#2. CTOR Potential Catalyst - The Company Announces $18Mn Closing Of Registered Direct Offering And Private Placement (Net Proceeds To Support LYMPHIR Commercial Launch).
Citius Oncology Announces Closing of $18Mn Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
CRANFORD, N.J., Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), ..., today announced the closing of its previously announced registered direct offering with a single healthcare-focused in-vest-or, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,284,404 shares of its common st-ock at a purchase price of $1.09 per share. In addition, the Company issued to the in-vest-or unregistered warrants to purchase up to 1,284,404 shares of common st-ock at an exercise price of $1.09 per share, which will be exercisable beginning on the effective date of st-ockholder approval of the issuance of the shares of common st-ock upon exercise of the warrants and will expire five years from the date of st-ockholder approval.
The Company also closed its previously announced private placement, priced at-the-market under Nasdaq rules, for the purchase and sale of 15,229,358 shares of common st-ock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 15,229,358 shares of the Company's common st-ock at a purchase price of $1.09 per share and accompanying warrant. The warrants issued in the private placement have an exercise price of $1.09 per share, will be exercisable beginning on the effective date of st-ockholder approval of the issuance of the shares of common st-ock upon exercise of the warrants, and will expire five years from the date of st-ockholder approval.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings.
The gross proceeds from the offerings, before deducting the placement agent's fees and other offering expenses payable by the Company, were approximately $18Mn. The Company intends to use the net proceeds from the offerings to support the commercial launch of LYMPHIR and for working capital and general corporate purposes.
...
Read the full article here. -----
#3. CTOR Potential Catalyst - A Major Milestone Notched As Company Announces Launch Of LYMPHIR.
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
LYMPHIR now available nationwide
CRANFORD, N.J., Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), ..., today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (r/r) Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
"LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for Citius Oncology. With a median time to response of 1.4 months in the Phase 3 trial, we believe LYMPHIR may offer rapid skin relief, among other benefits, to patients suffering from severe and debilitating itching common with the disease," said Leonard Mazur, Chairman and CEO of Citius Oncology... "This is our first marketed product and the culmination of years of development work and commercial preparation. LYMPHIR addresses a clear clinical need in a disease with limited treatment options. Ultimately, we expect LYMPHIR to be a meaningful addition to the treatment paradigm for CTCL and a value-driving catalyst for Citius Oncology shareholders. We estimate that LYMPHIR is entering a growing U.S. market valued at over $400Mn, with further upside opp's through international market access and potential expanded indications in the future. Our focus now is on execution to ensure that LYMPHIR reaches the patients who need it," added Mazur.
The FDA approval of LYMPHIR was based on data from Pivotal Study 302 (NCT01871727), which evaluated the efficacy and safety of LYMPHIR in patients with Stage I–III CTCL who had received at least one prior systemic treatment. The study demonstrated an Objective Response Rate (ORR) of 36.2%, with 84% of evaluable patients experiencing a reduction in skin tumor burden. Moreover, LYMPHIR demonstrated meaningful activity on severe pruritus (itchiness), a significant quality of life issue for CTCL patients. Median time to response was 1.4 months. Importantly, LYMPHIR was not associated with cumulative toxicity.
"LYMPHIR is an important new tool in the fight against CTCL. It is the only FDA-approved systemic therapy for CTCL in more than seven years," said Dr. Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Oncology... . "LYMPHIR's direct tumoricidal activity and transient T-regulatory cell depletion offer a powerful new approach to disease control without cumulative toxicity. As such, LYMPHIR's clinical profile makes it a compelling treatment option for physicians and patients facing the burden of relapsed or refractory CTCL."
...
Read the full article here. -----
#4. CTOR Potential Catalyst - A Key Agreement Represents A Significant Milestone In The Company's Global Expansion Strategy.
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE
LYMPHIR international availability extends to 19 markets outside the U.S.
CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), ..., today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim"), a leading pharmaceutical distributor based in Turkey, for LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed cytotoxin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Under the terms of the agreement, Er-Kim will be the exclusive distributor of LYMPHIR in Turkey and key Gulf Cooperation Council (GCC) countries, including Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.
The agreement expands Citius Oncology's international strategy to a total of 19 markets outside the U.S. leveraging Named Patient Programs. These programs provide access, where permitted by local law, and do not constitute commercial approval of LYMPHIR outside the United States. In October 2025, Citius Oncology announced access to LYMPHIR in Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia.
"This agreement represents a significant milestone in our global expansion strategy," said Leonard Mazur, Chairman and CEO of Citius Oncology... . "Er-Kim has deep industry experience and a strong track record of providing access to oncology therapies in complex international markets. Their local expertise and regulatory capabilities make them an ideal partner as we work to expand access to LYMPHIR in support of patients and providers across Turkey and the GCC."
...
Read the full article here. -----
#5. CTOR Potential Catalyst - A Maxim Group Analyst Tags CTOR With A $6 Target.
The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.
Michael Okunewitch, an analyst at Maxim Group covering the biotechnology sector, has suggested a $6.00 target for Citius Oncology as of 12/18/25 according to published info on the company’s website.
With this $6.00 target, there could be upside potential of over 400% for CTOR from its closing valuation Thursday. -----
(Nasdaq: CTOR) Recap - These 5 Potential Catalysts Could Draw Serious Buzz
#1. Could A Very Low Float Create An Environment For Heightened Volatility Potential?
#2. The Company Announces $18Mn Closing Of Registered Direct Offering And Private Placement (Net Proceeds To Support LYMPHIR Commercial Launch).
#3. A Major Milestone Notched As Company Announces Launch Of LYMPHIR.
#4. A Key Agreement Represents A Significant Milestone In The Company's Global Expansion Strategy.
#5. A Maxim Group Analyst Tags CTOR With A $6 Target. -----
We're officially kicking-off coverage on Citius Oncology, Inc. (Nasdaq: CTOR).
Be on the lookout for updates coming your way shortly. Talk soon.
Sincerely, Kai Parker StockWireNews
Sources: 1.) Internal CTOR estimates based on IQVIA market research
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/19/2025 and ending on 12/19/2025 to publicly disseminate information about (CTOR:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (CTOR:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/ctor-oypis/#details | 
Tidak ada komentar:
Posting Komentar